Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company has been selected to present at the 10th International Partnering Conference, BIO-Europe Spring® taking place at the Kistamässan Convention Center in Stockholm, Sweden over April 4-6.
The presentation will be given by Dr. Graham Lumsden, CEO of Motif Bio and will take place in Room E6/7 (level 0) on Tuesday, April 5 2016 at 14:15 CET.
BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe® and continues the tradition of providing life science companies with high calibre partnering opportunities. The conference annually attracts an international “who’s who” from biotech, pharma, and finance for three days networking and meetings.
Motif Bio plc
Graham Lumsden, Chief Executive Officer
David Huang, Chief Medical Officer
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / Dan Bate
+44 (0) 20 3829 5000
Northland Capital Partners Limited (Broker)
Patrick Claridge / David Hignell
John Howes / Rob Rees (Broking)
+44 (0) 207 382 1100
Walbrook PR Ltd. (Public and Investor Relations)
Paul McManus / Mike Wort
Main: +44 (0)20 7933 8780
Paul: +44 (0)7980 541 893
Mike: +44 (0)7900 608 002
MC Services AG (European IR)
+49 (0) 89 210 2280
Notes to Editors
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.